Vittorio Pengo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8169476/publications.pdf

Version: 2024-02-01

390 papers	23,061 citations	10956 71 h-index	10127 140 g-index
410 all docs	410 docs citations	410 times ranked	12075 citing authors

#	Article	IF	Citations
1	Incidence of Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Embolism. New England Journal of Medicine, 2004, 350, 2257-2264.	13.9	1,643
2	Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet, The, 1996, 348, 423-428.	6.3	1,270
3	Update of the guidelines for lupus anticoagulant detection. Journal of Thrombosis and Haemostasis, 2009, 7, 1737-1740.	1.9	1,055
4	The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica, 2007, 92, 199-205.	1.7	686
5	EULAR recommendations for the management of antiphospholipid syndrome in adults. Annals of the Rheumatic Diseases, 2019, 78, 1296-1304.	0.5	664
6	d-Dimer Testing to Determine the Duration of Anticoagulation Therapy. New England Journal of Medicine, 2006, 355, 1780-1789.	13.9	593
7	Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood, 2018, 132, 1365-1371.	0.6	573
8	Clinical course of highâ€risk patients diagnosed with antiphospholipid syndrome. Journal of Thrombosis and Haemostasis, 2010, 8, 237-242.	1.9	527
9	Chronic Thromboembolic Pulmonary Hypertension. Journal of the American College of Cardiology, 2013, 62, D92-D99.	1.2	503
10	Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a Task Force at the 13th International Congress on Antiphospholipid Antibodies. Lupus, 2011, 20, 206-218.	0.8	467
11	The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood, 1986, 68, 869-874.	0.6	436
12	Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood, 2011, 118, 4714-4718.	0.6	404
13	PAIMS 2: Alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. Journal of the American College of Cardiology, 1992, 20, 520-526.	1.2	337
14	Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenetics and Genomics, 2006, 16, 101-110.	0.7	326
15	Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clinical Pharmacology and Therapeutics, 2002, 72, 702-710.	2.3	322
16	Risk of Recurrence After a First Episode of Symptomatic Venous Thromboembolism Provoked by a Transient Risk Factor. Archives of Internal Medicine, 2010, 170, 1710-6.	4.3	300
17	Antibody profiles for the diagnosis of antiphospholipid syndrome. Thrombosis and Haemostasis, 2005, 93, 1147-1152.	1.8	271
18	The association between circulating antibodies against domain I of beta2â€glycoprotein I and thrombosis: an international multicenter study. Journal of Thrombosis and Haemostasis, 2009, 7, 1767-1773.	1.9	260

#	Article	IF	Citations
19	Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet, The, 2008, 371, 315-321.	6.3	257
20	Immunological specificity and mechanism of action of IgG lupus anticoagulants. Blood, 1987, 70, 69-76.	0.6	211
21	Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. Journal of Thrombosis and Haemostasis, 2020, 18, 2828-2839.	1.9	211
22	A Comparison of the Safety and Efficacy of Oral Antiocoagulation for the Treatment of Venous Thromboembolic Disease in Patients with or without Malignancy. Thrombosis and Haemostasis, 2000, 84, 805-810.	1.8	208
23	Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2018, 16, 809-813.	1.9	194
24	Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology, 2011, 50, 1684-1689.	0.9	193
25	The Risk for Fatal Pulmonary Embolism after Discontinuing Anticoagulant Therapy for Venous Thromboembolism. Annals of Internal Medicine, 2007, 147, 766.	2.0	192
26	Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Annals of the Rheumatic Diseases, 2011, 70, 1083-1086.	0.5	178
27	Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: An international and collaborative meta-analysis. Autoimmunity Reviews, 2014, 13, 281-291.	2.5	166
28	D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. Blood, 2014, 124, 196-203.	0.6	160
29	Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation.. Thrombosis and Haemostasis, 2011, 106, 868-876.	1.8	158
30	Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thrombosis and Haemostasis, 2006, 96, 337-341.	1.8	156
31	Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. Journal of Thrombosis and Haemostasis, 2006, 4, 1891-1896.	1.9	155
32	Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics. Thrombosis Research, 2016, 137, 178-183.	0.8	141
33	Oral Anticoagulant Therapy in Patients with Nonrheumatic Atrial Fibrillation and Risk of Bleeding. Thrombosis and Haemostasis, 2001, 85, 418-422.	1.8	138
34	A PKâ€“PD Model for Predicting the Impact of Age, CYP2C9, and VKORC1 Genotype on Individualization of Warfarin Therapy. Clinical Pharmacology and Therapeutics, 2007, 81, 529-538.	2.3	135
35	Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study. Blood, 2010, 115, 481-488.	0.6	134
36	Standardized Lowâ€“Molecular-Weight Heparin Bridging Regimen in Outpatients on Oral Anticoagulants Undergoing Invasive Procedure or Surgery. Circulation, 2009, 119, 2920-2927.	1.6	133

#	Article	IF	Citations
37	Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). Journal of Thrombosis and Thrombolysis, 2007, 23, 83-91.	1.0	131
38	Autoantibodies to Phospholipid-binding Plasma Proteins in Patients with Thrombosis and Phospholipid-reactive Antibodies. Thrombosis and Haemostasis, 1996, 75, 721-724.	1.8	126
39	Influence of different IgG anticardiolipin antibody cutâ€off values on antiphospholipid syndrome classification. Journal of Thrombosis and Haemostasis, 2008, 6, 1693-1696.	1.9	123
40	â€˜Criteriaâ€™ aPL tests: Report of a Task Force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010. Lupus, 2011, 20, 182-190.	0.8	122
41	Low drug levels and thrombotic complications in highâ€risk atrial fibrillation patients treated with direct oral anticoagulants. Journal of Thrombosis and Haemostasis, 2018, 16, 842-848.	1.9	120
42	Oral Anticoagulation Treatment in the Elderly. Archives of Internal Medicine, 2000, 160, 470.	4.3	119
43	Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmunity Reviews, 2015, 14, 192-200.	2.5	118
44	Autoimmune Antiphospholipid Antibodies Are Directed against a Cryptic Epitope Expressed when Î²2-Glycoprotein I Is Bound to a Suitable Surface. Thrombosis and Haemostasis, 1995, 73, 029-034.	1.8	114
45	Antiphospholipid syndrome: antibodies to Domain 1 of Î²2â€glycoprotein 1 correctly classify patients at risk. Journal of Thrombosis and Haemostasis, 2015, 13, 782-787.	1.9	113
46	Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillationâ^—â^—The investigators and institutions participating in the study are listed in the Appendix.. American Journal of Cardiology, 1998, 82, 433-437.	0.7	111
47	Worldwide Management of Oral Anticoagulant Therapy: the ISAM Study. Journal of Thrombosis and Thrombolysis, 2006, 21, 73-77.	1.0	111
48	Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy. Thrombosis Research, 2009, 123, 482-487.	0.8	106
49	The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases. Autoimmunity Reviews, 2019, 18, 406-414.	2.5	106
50	Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. Arthritis Care and Research, 2010, 62, 302-307.	1.5	105
51	Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. Immunologic Research, 2017, 65, 17-24.	1.3	97
52	Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples. Journal of Thrombosis and Haemostasis, 2007, 5, 925-930.	1.9	95
53	McMaster RAREâ€Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. Journal of Thrombosis and Haemostasis, 2018, 16, 1656-1664.	1.9	95
54	Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile. Journal of Thrombosis and Haemostasis, 2013, 11, 1527-1531.	1.9	94

#	Article	IF	Citations
55	Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment. Journal of Internal Medicine, 2011, 270, 110-122.	2.7	91
56	Risks factors for highly unstable response to oral anticoagulation: a case-control study. British Journal of Haematology, 2005, 129, 72-78.	1.2	86
57	Features associated with epilepsy in the antiphospholipid syndrome. Journal of Rheumatology, 2004, 31, 1344-8.	1.0	86
58	Risk stratification and outcomes in hemodynamically stable patients with acute pulmonary embolism: a prospective, multicentre, cohort study with three months of follow-up. Journal of Thrombosis and Haemostasis, 2009, 7, 938-944.	1.9	84
59	Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Journal of Thrombosis and Haemostasis, 2020, 18, 2126-2137.	1.9	84
60	The Redox Enzyme p66Shc Contributes to Diabetes and Ischemia-Induced Delay in Cutaneous Wound Healing. Diabetes, 2010, 59, 2306-2314.	0.3	83
61	Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants. Journal of Thrombosis and Haemostasis, 2019, 17, 1064-1072.	1.9	83
62	The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood, 1986, 68, 869-74.	0.6	83
63	The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. Seminars in Arthritis and Rheumatism, 2019, 49, 464-468.	1.6	79
64	A two-step coagulation test to identify antibeta2-glycoprotein I lupus anticoagulants. Journal of Thrombosis and Haemostasis, 2004, 2, 702-707.	1.9	78
65	Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A â€˜state-of-the-artâ€™ paper. European Heart Journal, 2014, 35, 2213-2223.	1.0	78
66	Antiphospholipid antibody ELISAs: Survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-Î²2-Glycoprotein I activity. Thrombosis Research, 2007, 120, 127-133.	0.8	77
67	Thrombotic Events during Oral Anticoagulant Treatment: Results of the Inception-cohort, Prospective, Collaborative ISCOAT Study. Thrombosis and Haemostasis, 1997, 78, 1438-1443.	1.8	77
68	dRVVT Is more Sensitive than KCT or TTI for Detecting Lupus Anticoagulant Activity of Anti-Î²2-glycoprotein I Autoantibodies. Thrombosis and Haemostasis, 1999, 81, 256-258.	1.8	75
69	Antiphospholipid syndrome and the heart: A case series and literature review. Autoimmunity Reviews, 2015, 14, 214-222.	2.5	75
70	Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial. Lupus, 2016, 25, 301-306.	0.8	75
71	Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. Nature Reviews Cardiology, 2019, 16, 113-130.	6.1	73
72	Reversal of excessive effect of regular anticoagulation. Blood Coagulation and Fibrinolysis, 1993, 4, 739-741.	0.5	71

#	Article	IF	Citations
73	Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature. Autoimmunity Reviews, 2007, 6, 196-202.	2.5	71
74	Detection of lupus anticoagulant in the era of direct oral anticoagulants. Autoimmunity Reviews, 2017, 16, 173-178.	2.5	71
75	Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PRogram for Oral Anticoagulant) Tj ETQq1 1 0.784314 rgBT /Overlock	8.4	71
76	Renal artery thrombosis and hypertension in a 13 year old girl with antiphospholipid syndrome.. Annals of the Rheumatic Diseases, 1990, 49, 184-187.	0.5	70
77	Lupus Anticoagulant (LA) Testing: Performance of Clinical Laboratories Assessed by a National Survey Using Lyophilized Affinity-purified Immunoglobulin with LA Activity. Clinical Chemistry, 2003, 49, 1608-1614.	1.5	70
78	Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant. Thrombosis Research, 2015, 135, 46-49.	0.8	70
79	Antibodies to Domain I of Î²2Glycoprotein I are in close relation to patients risk categories in Antiphospholipid Syndrome (APS). Thrombosis Research, 2011, 128, 583-586.	0.8	68
80	Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study. Journal of Thrombosis and Haemostasis, 2016, 14, 2194-2201.	1.9	68
81	A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thrombosis and Haemostasis, 2000, 84, 805-10.	1.8	64
82	VKORC1,CYP2C9andCYP4F2genetic-based algorithm for warfarin dosing: an Italian retrospective study. Pharmacogenomics, 2011, 12, 15-25.	0.6	62
83	Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study. Thrombosis and Haemostasis, 2018, 47, 639-646.	1.8	62
84	Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. Arthritis Care and Research, 2021, 73, 1490-1501.	1.5	60
85	Ferritin in the antiphospholipid syndrome and its catastrophic variant (cAPS). Lupus, 2013, 22, 1327-1335.	0.8	59
86	Correct laboratory approach to APS diagnosis and monitoring. Autoimmunity Reviews, 2013, 12, 832-834.	2.5	59
87	Prevalence and clinical correlations of antibodies against six beta2-glycoprotein-I-related peptides in the antiphospholipid syndrome. Journal of Clinical Immunology, 2003, 23, 377-383.	2.0	57
88	What Have We Learned about Antiphospholipid Syndrome from Patients and Antiphospholipid Carrier Cohorts?. Seminars in Thrombosis and Hemostasis, 2012, 38, 322-327.	1.5	57
89	Impact of the CYP4F2 p.V433M Polymorphism on Coumarin Dose Requirement: Systematic Review and Meta-Analysis. Clinical Pharmacology and Therapeutics, 2012, 92, 746-756.	2.3	56
90	IPO-V2: A prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascular accidents in the first year after acute myocardial infarction. Journal of the American College of Cardiology, 1994, 23, 27-34.	1.2	53

#	Article	IF	Citations
91	The left atrial appendage: from embryology to prevention of thromboembolism. European Heart Journal, 2017, 38, ehw159.	1.0	53
92	Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function. Thrombosis Research, 2009, 123, 444-451.	0.8	52
93	Tetra positive thrombotic antiphospholipid syndrome: Major contribution of antiâ€phosphatidylâ€serine/prothrombin antibodies to lupus anticoagulant activity. Journal of Thrombosis and Haemostasis, 2020, 18, 1124-1132.	1.9	51
94	The Management of Oral Anticoagulant Therapy: The Patientâ€™s Point of View. Thrombosis and Haemostasis, 2000, 83, 49-53.	1.8	50
95	Residual Venous Obstruction, alone and in Combination with D-Dimer, as a Risk Factor for Recurrence after Anticoagulation Withdrawal following a First Idiopathic Deep Vein Thrombosis in the Prolong Study. European Journal of Vascular and Endovascular Surgery, 2010, 39, 356-365.	0.8	50
96	The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation. PLoS ONE, 2015, 10, e0124719.	1.1	50
97	Long-term use of vitamin K antagonists and incidence of cancer: a population-based study. Blood, 2011, 117, 1707-1709.	0.6	49
98	Antiphosphatidylserine/prothrombin antibodies as biomarkers to identify severe primary antiphospholipid syndrome. Clinical Chemistry and Laboratory Medicine, 2017, 55, 890-898.	1.4	49
99	Lupus anticoagulant identifies two distinct groups of patients with different antibody patterns. Thrombosis Research, 2018, 172, 172-178.	0.8	49
100	Accuracy of a Portable Prothrombin Time Monitor (Coagucheck) in Patients on Chronic Oral Anticoagulant Therapy. Thrombosis Research, 2000, 100, 279-286.	0.8	47
101	Plasma exchange for the management of the catastrophic antiphospholipid syndrome: importance of the type of fluid replacement. Journal of Internal Medicine, 2008, 264, 201-203.	2.7	46
102	Immunological specificity and mechanism of action of IgG lupus anticoagulants. Blood, 1987, 70, 69-76.	0.6	46
103	A Comparison of Lupus Anticoagulantâ€“Positive Patients With Clinical Picture of Antiphospholipid Syndrome and Those Without. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, e309-10.	1.1	43
104	The predictive ability of bleeding risk stratification models in very old patients on vitaminÂK antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study. Journal of Thrombosis and Haemostasis, 2013, 11, 1053-1058.	1.9	43
105	Antibodies to Domain 4/5 (Dm4/5) of Î²2-Glycoprotein 1 (Î²2GP1) in different antiphospholipid (aPL) antibody profiles. Thrombosis Research, 2015, 136, 161-163.	0.8	42
106	Lower versus standard intensity oral anticoagulant therapy (OAT) in elderly warfarin-experienced patients with non-valvular atrial fibrillation. Thrombosis and Haemostasis, 2010, 103, 442-449.	1.8	41
107	A combination therapy protocol of plasmapheresis, intravenous immunoglobulins and betamethasone to treat anti-Ro/La-related congenital atrioventricular block. A case series and review of the literature. Autoimmunity Reviews, 2013, 12, 768-773.	2.5	41
108	High blood ketone body concentration in Type 2 non-insulin dependent diabetic patients. Journal of Endocrinological Investigation, 1996, 19, 99-105.	1.8	40

#	Article	IF	Citations
109	The role of platelets in antiphospholipid syndrome. Platelets, 2017, 28, 762-766.	1.1	40
110	Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Twoâ€year outcomes after the study closure. Journal of Thrombosis and Haemostasis, 2021, 19, 531-535.	1.9	40
111	The long-term risk of cancer in patients with a first episode of venous thromboembolism. Journal of Thrombosis and Haemostasis, 2009, 7, 546-551.	1.9	39
112	Thrombocytopenia in highâ€risk patients with antiphospholipid syndrome. Journal of Thrombosis and Haemostasis, 2018, 16, 529-532.	1.9	39
113	Characteristics of Patients With Antiphospholipid Antibody Positivity in the <scp>APS ACTION</scp> International Clinical Database and Repository. Arthritis Care and Research, 2022, 74, 324-335.	1.5	39
114	A Comparison of a Moderate with Moderate-high Intensity Oral Anticoagulant Treatment in Patients with Mechanical Heart Valve Prostheses. Thrombosis and Haemostasis, 1997, 77, 0839-0844.	1.8	39
115	High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: â€˜PROSâ€™ and â€˜CONSâ€™. Autoimmunity Reviews, 2012, 11, 577-580.	2.5	38
116	Platelet and endothelial activation in catastrophic and quiescent antiphospholipid syndrome. Thrombosis and Haemostasis, 2013, 109, 901-908.	1.8	37
117	The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibodyâ€“Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository. Arthritis Care and Research, 2019, 71, 134-141.	1.5	37
118	Reduction in all-cause mortality in COVID-19 patients on chronic oral anticoagulation: A population-based propensity score matched study. International Journal of Cardiology, 2021, 329, 266-269.	0.8	37
119	Some Patients with Antiphospholipid Syndrome Express hitherto Undescribed Antibodies to Cardiolipin-binding Proteins. Thrombosis and Haemostasis, 2001, 85, 57-62.	1.8	36
120	Prevalence of heart diseases in patients with pulmonary embolism with and without peripheral venous thrombosis. European Journal of Internal Medicine, 2009, 20, 470-473.	1.0	36
121	A combination therapy to treat second-degree anti-Ro/La-related congenital heart block. A strategy to avoid stable third-degree heart block?. Lupus, 2012, 21, 666-671.	0.8	36
122	Variability in Exposure of Epitope G40-R43 of Domain I in Commercial Anti-Beta2-Glycoprotein I IgG ELISAs. PLoS ONE, 2013, 8, e71402.	1.1	36
123	Mechanical prosthetic heart valves: Quality of anticoagulation and thromboembolic risk. The observational multicenter PLECTRUM study. International Journal of Cardiology, 2018, 267, 68-73.	0.8	36
124	Sex, age and normal postâ€anticoagulation Dâ€dimer as risk factors for recurrence after idiopathic venous thromboembolism in the Prolong study extension. Journal of Thrombosis and Haemostasis, 2010, 8, 1933-1942.	1.9	35
125	Epidemiology and Management of Patients With Acute Coronary Syndromes in Contemporary Real-World Practice: Evolving Trends From the EYESHOT Study to the START-ANTIPLATELET Registry. Angiology, 2018, 69, 795-802.	0.8	35
126	Effectiveness and safety of a management protocol to correct over-anticoagulation with oral vitamin K: a retrospective study of 1,043 cases. Journal of Thrombosis and Thrombolysis, 2009, 27, 340-347.	1.0	34

#	Article	IF	Citations
127	Antiphospholipid syndrome: critical analysis of the diagnostic path. Lupus, 2010, 19, 428-431.	0.8	34
128	ISTH guidelines on Lupus Anticoagulant testing. Thrombosis Research, 2012, 130, S76-S77.	0.8	34
129	Patients with isolated pulmonary embolism in comparison to those with deep venous thrombosis. Differences in characteristics and clinical evolution. European Journal of Internal Medicine, 2019, 69, 64-70.	1.0	34
130	Balloon Pulmonary Angioplasty in Patients With Chronic Thromboembolic Pulmonary Hypertensionã€€â€• A Systematic Review and Meta-Analysis â€•. Circulation Journal, 2019, 83, 1660-1667.	0.7	34
131	Simple and Safe Method to Prepare Patients With Prosthetic Heart Valves for Surgical Dental Procedures. Clinical and Applied Thrombosis/Hemostasis, 2000, 6, 90-93.	0.7	33
132	Triple Antiphospholipid (aPL) Antibodies Positivity Is Associated With Pregnancy Complications in aPL Carriers: A Multicenter Study on 62 Pregnancies. Frontiers in Immunology, 2019, 10, 1948.	2.2	33
133	Use of D-dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study. Journal of Thrombosis and Thrombolysis, 2009, 28, 381-388.	1.0	32
134	Deep Venous Thrombosis After Surgery for Inflammatory Bowel Disease: Is Standard Dose Low Molecular Weight Heparin Prophylaxis Enough?. World Journal of Surgery, 2010, 34, 1629-1636.	0.8	32
135	The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism. Journal of Thrombosis and Haemostasis, 2018, 16, 1994-2002.	1.9	32
136	The challenges of lupus anticoagulants. Expert Review of Hematology, 2016, 9, 389-400.	1.0	31
137	Diagnostics and treatment of thrombotic antiphospholipid syndrome (APS): A personal perspective. Thrombosis Research, 2018, 169, 35-40.	0.8	31
138	Low-Intensity Oral Anticoagulant Plus Low-Dose Aspirin During the First Six Months Versus Standard-Intensity Oral Anticoagulant Therapy After Mechanical Heart Valve Replacement: A Pilot Study of Low-Intensity Warfarin and Aspirin in Cardiac Prostheses (LIWACAP). Clinical and Applied Thrombosis/Hemostasis, 2007, 13, 241-248.	0.7	30
139	A contribution to the debate on the laboratory criteria that define the antiphospholipid syndrome. Journal of Thrombosis and Haemostasis, 2008, 6, 1048-1049.	1.9	30
140	Recovery from catastrophic antiphospholipid syndrome by a plasma exchange procedure: report of four cases and review of the literature. Autoimmunity Reviews, 2009, 8, 297-301.	2.5	30
141	Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA). Thrombosis Research, 2010, 126, 150-153.	0.8	30
142	Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20Âyears ago. Internal and Emergency Medicine, 2017, 12, 1109-1119.	1.0	30
143	Thrombotic events during oral anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study: ISCOAT study group (Italian Study on Complications of Oral) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50		
144	Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multicenter Inception Cohort Study. Thrombosis and Haemostasis, 2001, 85, 418-22.	1.8	30

#	Article	IF	Citations
145	Apolipoprotein E (APOE) and warfarin dosing in an Italian population. European Journal of Clinical Pharmacology, 2005, 61, 781-783.	0.8	29
146	Antiphosphatidylserine/prothrombin antibodies in primary antiphospholipid syndrome. Lupus, 2012, 21, 787-789.	0.8	29
147	Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. Journal of Thrombosis and Haemostasis, 2012, 10, 1979-1987.	1.9	29
148	APS - Diagnostics and challenges for the future. Autoimmunity Reviews, 2016, 15, 1031-1033.	2.5	29
149	Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (<scp>APS</scp>) in the <scp>APS</scp> Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study. BJOG: an International Journal of Obstetrics and Gynaecology, 2019, 126, 656-661.	1.1	29
150	Autoimmune antiphospholipid antibodies are directed against a cryptic epitope expressed when beta 2-glycoprotein I is bound to a suitable surface. Thrombosis and Haemostasis, 1995, 73, 29-34.	1.8	29
151	Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thrombosis and Haemostasis, 1996, 75, 721-4.	1.8	29
152	Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention. American Journal of Hematology, 2009, 84, 579-583.	2.0	28
153	Antiphospholipid Syndrome in Chronic Thromboembolic Pulmonary Hypertension: A Well-Defined Subgroup of Patients. Thrombosis and Haemostasis, 2019, 119, 1403-1408.	1.8	28
154	Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry. Lupus, 2020, 29, 1353-1363.	0.8	28
155	Adenosine Diphosphate (ADP)-Induced â¤-Granules Release from Platelets of Native Whole Blood Is Reduced by Ticlopidine but Not by Aspirin or Dipyridamole. Thrombosis and Haemostasis, 1986, 56, 147-150.	1.8	28
156	Î²2-GlycoproteinÂI binds to thrombin and selectively inhibits the enzyme procoagulant functions. Journal of Thrombosis and Haemostasis, 2013, 11, 1093-1102.	1.9	27
157	Relationship between antiphosphatidylserine/prothrombin and conventional antiphospholipid antibodies in primary antiphospholipid syndrome. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1265-70.	1.4	27
158	The vexed question of whether or not to measure levels of direct oral anticoagulants before surgery or invasive procedures. Internal and Emergency Medicine, 2018, 13, 1029-1036.	1.0	27
159	Additional laboratory tests to improve on the diagnosis of antiphospholipid syndrome. Journal of Thrombosis and Haemostasis, 2020, 18, 1846-1848.	1.9	27
160	A Randomized Trial of Pharmacogenetic Warfarin Dosing in NaÃ¯ve Patients with Non-Valvular Atrial Fibrillation. PLoS ONE, 2015, 10, e0145318.	1.1	27
161	Reasons for and consequences of vitamin K antagonist discontinuation in very elderly patients with nonâ€valvular atrial fibrillation. Journal of Thrombosis and Haemostasis, 2016, 14, 2124-2131.	1.9	26
162	Catastrophic antiphospholipid syndrome: Lessons from 14 cases successfully treated in a single center. A narrative report. Journal of Autoimmunity, 2018, 93, 124-130.	3.0	26

#	Article	IF	Citations
163	Antiphospholipid antibodies are not present in the membrane of gel-filtered platelets of patients with IgG anticardiolipin antibodies, lupus anticoagulant and thrombosis. Blood Coagulation and Fibrinolysis, 1993, 4, 425-428.	0.5	25
164	[Anti-Î²2 Glycoprotein Iâ€"Î²2 Glycoprotein I] immune complexes in patients with antiphospholipid syndrome and other autoimmune diseases. Lupus, 1999, 8, 121-126.	0.8	25
165	Hospitalized patients with atrial fibrillation compared to those included in recent trials on novel oral anticoagulants: A population-based study. European Journal of Internal Medicine, 2013, 24, 318-323.	1.0	25
166	Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry. Internal and Emergency Medicine, 2018, 13, 1051-1058.	1.0	25
167	Prevalence of antiphospholipid (aPL) antibodies among patients with chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis. Internal and Emergency Medicine, 2019, 14, 521-527.	1.0	25
168	Utilization of Dilute Russellâ€™s Viper Venom Time to Detect Autoantibodies against Î²2-Glycoprotein I which Express Anticoagulant Activity in the Presence but not in the Absence of Exogenous Phospholipids. Thrombosis and Haemostasis, 1997, 77, 123-126.	1.8	25
169	The SAME-TT2R2 score predicts the quality of anticoagulation control in patients with acute VTE. Thrombosis and Haemostasis, 2016, 115, 1101-1108.	1.8	24
170	Chemical synthesis and characterization of wildâ€type and biotinylated Nâ€terminal domain 1â€“64 of Î²2â€glycoprotein I. Protein Science, 2010, 19, 1065-1078.	3.1	23
171	Circulating Î²2 glycoprotein I-IgG anti-Î²2 glycoprotein I immunocomplexes in patients with definite Antiphospholipid Syndrome. Lupus, 2012, 21, 784-786.	0.8	23
172	Comparison of HAS-BLED and HAS-BED Versus CHADS 2 and CHA 2 DS 2 VASC Stroke and Bleeding Scores in Patients With Atrial Fibrillation. American Journal of Cardiology, 2017, 119, 1012-1016.	0.7	23
173	Laboratory Diagnostics of Antiphospholipid Syndrome. Seminars in Thrombosis and Hemostasis, 2018, 44, 439-444.	1.5	23
174	Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry. Journal of the American Heart Association, 2019, 8, e012596.	1.6	23
175	Effect of <scp>CYP</scp>4F2,<scp>VKORC</scp>1, and <scp>CYP</scp>2C9 in Influencing Coumarin Dose: A Singleâ€Patient Data Metaâ€Analysis in More Than 15,000 Individuals. Clinical Pharmacology and Therapeutics, 2019, 105, 1477-1491.	2.3	23
176	Procoagulant Effect of Antiâ€"Î²2-Glycoprotein I Antibodies With Lupus Anticoagulant Activity. Blood, 1999, 94, 3814-3819.	0.6	22
177	Antibodies to oxidized LDL/Î²2-glycoprotein I in antiphospholipid syndrome patients with venous and arterial thromboembolism. Thrombosis Research, 2008, 122, 556-559.	0.8	22
178	The long-term risk of cancer in patients with venous thromboembolism does not exceed that expected in the general population after the first 6 months. Journal of Thrombosis and Haemostasis, 2010, 8, 1126-7.	1.9	22
179	APS â€“ controversies in diagnosis and management, critical overview of current guidelines. Thrombosis Research, 2011, 127, S51-S52.	0.8	22
180	More on: laboratory investigation of lupus anticoagulants: mixing studies are sometimes required. Journal of Thrombosis and Haemostasis, 2011, 9, 2126-2127.	1.9	22

#	Article	IF	Citations
181	Laboratory testing for antiphospholipid syndrome. International Journal of Laboratory Hematology, 2016, 38, 27-31.	0.7	22
182	Effectiveness and safety of oral anticoagulation with non-vitamin K antagonists compared to well-managed vitamin K antagonists in naÃ¯ve patients with non-valvular atrial fibrillation: Propensity score matched cohort study. International Journal of Cardiology, 2017, 249, 198-203.	0.8	22
183	A Comparison Between Six- and Four-Week Intervals in Surveillance of Oral Anticoagulant Treatment. American Journal of Clinical Pathology, 2003, 120, 944-947.	0.4	21
184	Residual vein thrombosis and serial D-dimer for the long-term management of patients with deep venous thrombosis. Thrombosis Research, 2017, 154, 35-41.	0.8	21
185	Gender-Related Differences in Antiplatelet Therapy and Impact on 1-Year Clinical Outcome in Patients Presenting With ACS: The START ANTIPLATELET Registry. Angiology, 2019, 70, 257-263.	0.8	21
186	Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry. Internal and Emergency Medicine, 2021, 16, 379-387.	1.0	21
187	Prevalence and predictors of dual antiplatelet therapy prolongation beyond one year in patients with acute coronary syndrome. PLoS ONE, 2017, 12, e0186961.	1.1	21
188	Assessment of patient capability to self-adjust oral anticoagulant dose: a multicenter study on home use of portable prothrombin time monitor (COAGUCHECK). Haematologica, 2000, 85, 826-31.	1.7	21
189	Prevention of thromboembolism in patients with mitral stenosis and associated atrial fibrillation: effectiveness of low intensity (INR target 2) oral anticoagulant treatment. Thrombosis and Haemostasis, 2003, 89, 760-764.	1.8	20
190	Managing dentoalveolar surgical procedures in patients taking new oral anticoagulants. Odontology / the Society of the Nippon Dental University, 2015, 103, 258-263.	0.9	20
191	Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant. BMC Medicine, 2017, 15, 54.	2.3	20
192	Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry). American Journal of Cardiology, 2019, 124, 1662-1668.	0.7	20
193	Discovery and characterization of 2 novel subpopulations of aPS/PT antibodies in patients at high risk of thrombosis. Blood Advances, 2019, 3, 1738-1749.	2.5	20
194	The J-elongated conformation of Î²2-glycoprotein I predominates in solution: implications for our understanding of antiphospholipid syndrome. Journal of Biological Chemistry, 2020, 295, 10794-10806.	1.6	20
195	A simple scheme to initiate oral anticoagulant treatment in outpatients with nonrheumatic atrial fibrillation. American Journal of Cardiology, 2001, 88, 1214-1216.	0.7	19
196	Association of the G20210A mutation in the factor II gene with systemic embolism in nonvalvular atrial fibrillation. American Journal of Cardiology, 2002, 90, 545-547.	0.7	19
197	Clinical management of rivaroxaban-treated patients. Expert Opinion on Pharmacotherapy, 2013, 14, 655-667.	0.9	19
198	An Approach to Differential Diagnosis of Antiphospholipid Antibody Syndrome and Related Conditions. Scientific World Journal, The, 2014, 2014, 1-8.	0.8	19

#	Article	IF	Citations
199	Different safety profiles of oral anticoagulants in very elderly non-valvular atrial fibrillation patients. A retrospective propensity score matched cohort study. International Journal of Cardiology, 2018, 265, 103-107.	0.8	19
200	International collaborative study for the calibration of proposed International Standards for thromboplastin, rabbit, plain, and for thromboplastin, recombinant, human, plain. Journal of Thrombosis and Haemostasis, 2018, 16, 142-149.	1.9	19
201	Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository. Journal of Rheumatology, 2021, 48, 541-547.	1.0	19
202	15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Treatment Trends Report. , 2017, , 317-338.		19
203	Purification of anticardiolipin and lupus anticoagulant activities by using cardiolipin immobilized on agarose beads. Thrombosis Research, 1993, 72, 423-430.	0.8	18
204	Thrombophilia in young patients with cryptogenic stroke and patent foramen ovale (PFO). Thrombosis and Haemostasis, 2007, 98, 906-907.	1.8	18
205	DOAC plasma levels measured by chromogenic antiâ€Xa assays and HPLCâ€UV in apixabanâ€•and rivaroxabanâ€treated patients from the STARTâ€Register. International Journal of Laboratory Hematology, 2020, 42, 214-222.	0.7	18
206	The management of oral anticoagulant therapy: the patient's point of view. Thrombosis and Haemostasis, 2000, 83, 49-53.	1.8	18
207	To treat or not to treat very elderly naÃ¯ve patients with atrial fibrillation with vitamin K antagonists (VKA): results from the VENPAF cohort. Internal and Emergency Medicine, 2015, 10, 795-804.	1.0	17
208	Real-world persistence with direct oral anticoagulants (DOACs) in naÃ¯ve patients with non-valvular atrial fibrillation. International Journal of Cardiology, 2019, 288, 72-75.	0.8	17
209	Molecular mapping of Î±-thrombin (Î±T)/Î²2-glycoprotein I (Î²2GpI) interaction reveals how Î²2GpI affects Î±T functions. Biochemical Journal, 2016, 473, 4629-4650.	1.7	16
210	Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review. Clinical Reviews in Allergy and Immunology, 2017, 53, 28-39.	2.9	16
211	Population differences in S-warfarin pharmacokinetics among African Americans, Asians and whites: their influence on pharmacogenetic dosing algorithms. Pharmacogenomics Journal, 2017, 17, 494-500.	0.9	16
212	Antiplatelet treatment in acute coronary syndrome patients: Real-world data from the START-Antiplatelet Italian Registry. PLoS ONE, 2019, 14, e0219676.	1.1	16
213	Arterial thrombosis in antiphospholipid syndrome (APS): Clinical approach and treatment. A systematic review. Blood Reviews, 2021, 48, 100788.	2.8	16
214	Prevalence of aPhosphatidylserine/prothrombin antibodies and association with antiphospholipid antibody profiles in patients with antiphospholipid syndrome: A systematic review and meta-analysis. Thrombosis Research, 2022, 214, 106-114.	0.8	16
215	Comorbidities, alone and in combination with D-dimer, as risk factors for recurrence after a first episode of unprovoked venous thromboembolism in the extended follow-up of the PROLONG study. Thrombosis and Haemostasis, 2010, 103, 1152-1160.	1.8	15
216	Duration of anticoagulation after isolated pulmonary embolism. European Respiratory Journal, 2016, 47, 1429-1435.	3.1	15

#	Article	IF	Citations
217	Insight into the hypercoagulable state of highâ€risk thrombotic APS patients: Contribution of aÎ²2GPI and aPS/PT antibodies. Journal of Thrombosis and Haemostasis, 2021, 19, 805-813.	1.9	15
218	Diagnosis and therapy of antiphospholipid syndrome. Polish Archives of Internal Medicine, 2015, 125, 672-677.	0.3	15
219	Comparison between Routine Laboratory Prothrombin Time Measurements and Fingerstick Determinations Using a Near-Patient Testing Device (Pro-TimeÂ®). Thrombosis Research, 2000, 97, 495-498.	0.8	14
220	Efficacy and safety of nadroparin in the treatment of pregnant women with antiphospholipid syndrome: a prospective cohort study. Lupus, 2005, 14, 120-128.	0.8	14
221	Antiphospholipid syndrome: interpretation of laboratory data. Journal of Thrombosis and Haemostasis, 2011, 9, 402-403.	1.9	14
222	Major bleeding in patients undergoing PCI and triple or dual antithrombotic therapy: a parallel-cohort study. Journal of Thrombosis and Thrombolysis, 2013, 35, 178-184.	1.0	14
223	Primary thromboprophylaxis with low-dose aspirin and antiphospholipid antibodies: Pro's and Con's. Autoimmunity Reviews, 2017, 16, 1103-1108.	2.5	14
224	Laboratory criteria for antiphospholipid syndrome: reply. Journal of Thrombosis and Haemostasis, 2018, 16, 2117-2119.	1.9	14
225	Use of a new silica clotting time for diagnosing lupus anticoagulant in patients who meet the clinical criteria for antiphospholipid syndrome. Journal of Clinical Laboratory Analysis, 2006, 20, 15-18.	0.9	13
226	The Paradox of the Lupus Anticoagulant: History and Perspectives. Seminars in Thrombosis and Hemostasis, 2014, 40, 860-865.	1.5	13
227	Lupus Anticoagulant Testing: Diluted Russell Viper Venom Time (dRVVT). Methods in Molecular Biology, 2017, 1646, 169-176.	0.4	13
228	Clinical value of anti-domain I-Î²2Glycoprotein 1 antibodies in antiphospholipid antibody carriers. A single centre, prospective observational follow-up study. Clinica Chimica Acta, 2018, 485, 74-78.	0.5	13
229	The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis. Thrombosis Research, 2019, 175, 32-36.	0.8	13
230	Anti-phosphatidyl-serine/prothrombin antibodies (aPS/PT) in isolated lupus anticoagulant (LA): is their presence linked to dual test positivity?. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1950-1953.	1.4	13
231	Impact of COVID-19 and COVID-19 vaccination on high-risk patients with antiphospholipid syndrome: a nationwide survey. Rheumatology, 2022, 61, SI136-SI142.	0.9	13
232	Diabetic ketosis activates lymphomonocyte-inducible nitric oxide synthase. Diabetic Medicine, 2002, 19, 777-783.	1.2	12
233	Knowledges about herbal products among subjects on warfarin therapy and patientâ€“physician relationship: a pilot study. Pharmacoepidemiology and Drug Safety, 2007, 16, 1014-1017.	0.9	12
234	A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty. Journal of Thrombosis and Thrombolysis, 2011, 31, 233-234.	1.0	12

#	Article	IF	Citations
235	Reduction of annexin A5 anticoagulant ratio identifies antiphospholipid antibodyâ€positive patients with adverse clinical outcomes. Journal of Thrombosis and Haemostasis, 2017, 15, 1412-1421.	1.9	12
236	Clinical conundrums in antithrombotic therapy management: A Delphi Consensus panel. International Journal of Cardiology, 2017, 249, 249-256.	0.8	12
237	Impact of Chronic Renal Failure on Ischemic and Bleeding Events at 1 Year in Patients With Acute Coronary Syndrome (from the Multicenter START ANTIPLATELET Registry). American Journal of Cardiology, 2018, 122, 936-943.	0.7	12
238	Optimizing quality care for the oral vitamin K antagonists (VKAs). Hematology American Society of Hematology Education Program, 2018, 2018, 332-338.	0.9	12
239	Reversal of excessive effect of regular anticoagulation: low oral dose of phytonadione (vitamin K1) compared with warfarin discontinuation. Blood Coagulation and Fibrinolysis, 1993, 4, 739-41.	0.5	12
240	Binding of autoimmune cardiolipin-reactive antibodies to heparin: A mechanism of thrombosis?. Thrombosis Research, 1995, 78, 371-378.	0.8	11
241	Immunosuppressive treatment in a heart transplantation candidate with antiphospholipid syndrome. Clinical Rheumatology, 1996, 15, 504-507.	1.0	11
242	The Diagnosis of the Antiphospholipid Syndrome. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2006, 35, 175-180.	0.5	11
243	Anti-Î²2-glycoprotein I ELISA assay: The influence of different antigen preparations. Thrombosis and Haemostasis, 2009, 101, 789-791.	1.8	11
244	Laboratory tests during direct oral anticoagulant treatment? Yes. Internal and Emergency Medicine, 2013, 8, 371-372.	1.0	11
245	Assessing the relative potency of (S)- and (R)-warfarin with a new PK-PD model, in relation to VKORC1 genotypes. European Journal of Clinical Pharmacology, 2017, 73, 699-707.	0.8	11
246	Point of Care Testing (POCT) to assess drug concentration in patients treated with non-vitamin K antagonist oral anticoagulants (NOACs). Thrombosis Research, 2018, 163, 100-104.	0.8	11
247	Bleeding and thrombotic complications during treatment with direct oral anticoagulants or vitamin K antagonists in venous thromboembolic patients included in the prospective, observational START2-register. BMJ Open, 2020, 10, e040449.	0.8	11
248	The Risk of Overdiagnosis of Antiphospholipid Antibody Syndrome. Thrombosis and Haemostasis, 2001, 86, 933-933.	1.8	10
249	Argatroban in the management of heparin-induced thrombocytopenia. Vascular Health and Risk Management, 2010, 6, 813.	1.0	10
250	Secondary prevention in thrombotic antiphospholipid syndrome. Lupus, 2012, 21, 734-735.	0.8	10
251	Biological variation of INR in stable patients on long-term anticoagulation with warfarin. Thrombosis Research, 2012, 130, 535-537.	0.8	10
252	Clinical Relevance of Î²2-Glycoprotein-I Plasma Levels in Antiphospholipid Syndrome (APS). Current Rheumatology Reports, 2014, 16, 424.	2.1	10

#	Article	IF	Citations
253	Consequences of warfarin suspension after major bleeding in very elderly patients with non valvular atrial fibrillation. Thrombosis and Haemostasis, 2017, 117, 1828-1830.	1.8	10
254	D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study. Internal and Emergency Medicine, 2020, 15, 453-462.	1.0	10
255	Additional laboratory tests to improve on the diagnosis of antiphospholipid syndrome: Response from Pengo. Journal of Thrombosis and Haemostasis, 2020, 18, 3118-3119.	1.9	10
256	Prothrombin Is Responsible for the Lupus Cofactor Phenomenon in a Patient with Lupus Anticoagulant/Hypoprothrombinemia Syndrome. TH Open, 2020, 04, e40-e44.	0.7	10
257	Peripheral arterial disease has a strong impact on cardiovascular outcome in patients with acute coronary syndromes: from the START Antiplatelet registry. International Journal of Cardiology, 2021, 327, 176-182.	0.8	10
258	A comparison between six- and four-week intervals in surveillance of oral anticoagulant treatment. American Journal of Clinical Pathology, 2003, 120, 944-7.	0.4	10
259	Bileaflet mechanical heart valve closing sounds: in vitro classification by phonocardiographic analysis. Journal of Artificial Organs, 2009, 12, 172-181.	0.4	9
260	Cancer prevention and vitamin K antagonists: An overview. Thrombosis Research, 2010, 125, S103-S105.	0.8	9
261	Interpretation of laboratory data and need for reference laboratories. Lupus, 2012, 21, 732-733.	0.8	9
262	Family history of venous thrombosis or sudden death as a risk factor for venous thromboembolism. Thrombosis and Haemostasis, 2012, 107, 1191-1192.	1.8	9
263	Minimizing the risk of hemorrhagic stroke during anticoagulant therapy for atrial fibrillation. Expert Opinion on Drug Safety, 2015, 14, 683-695.	1.0	9
264	Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. Journal of Thrombosis and Haemostasis, 2019, 17, 2069-2080.	1.9	9
265	Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome. Internal and Emergency Medicine, 2021, 16, 1583-1591.	1.0	9
266	Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (â€˜Registryâ€™). Lupus Science and Medicine, 2022, 9, e000633.	1.1	9
267	Sex and anticoagulation in patients with idiopathic venous thromboembolism. Lancet, The, 2006, 368, 342-343.	6.3	8
268	Management of Oral Anticoagulant Treatment in Patients with Venous Thromboembolism. Seminars in Thrombosis and Hemostasis, 2006, 32, 781-786.	1.5	8
269	Emerging anticoagulants. Expert Opinion on Emerging Drugs, 2011, 16, 31-44.	1.0	8
270	Standardization of lupus anticoagulant. Feasibility study of a calibration model to minimize between-method variability. Thrombosis Research, 2011, 127, 589-594.	0.8	8

#	Article	IF	Citations
271	Falseâ€negative or falseâ€positive: laboratory diagnosis of lupus anticoagulant at the time of commencement of anticoagulant: a rebuttal. Journal of Thrombosis and Haemostasis, 2011, 9, 1435-1436.	1.9	8
272	Aspirin and recurrent venous thromboembolism in patients with symptomatic atherosclerosis: retrospective cohort study. Journal of Thrombosis and Haemostasis, 2012, 10, 2205-2206.	1.9	8
273	Risk-based secondary prevention of obstetric antiphospholipid syndrome. Lupus, 2012, 21, 741-743.	0.8	8
274	The negative predictive value of D-dimer on the risk of recurrent venous thromboembolism in patients with multiple previous events: A prospective cohort study (the PROLONG PLUS study). American Journal of Hematology, 2012, 87, 713-715.	2.0	8
275	Investigational anticoagulants for hematological conditions: a new generation of therapies. Expert Opinion on Investigational Drugs, 2013, 22, 1281-1294.	1.9	8
276	Can we use NOACS in APS?. Autoimmunity Reviews, 2019, 18, 102408.	2.5	8
277	An oral vitamin K protocol to reverse over-anticoagulation in patients presenting with an International Normalised Ratio above 10.0. Thrombosis and Haemostasis, 2009, 101, 410-411.	1.8	8
278	dRVVT is more sensitive than KCT or TTI for detecting lupus anticoagulant activity of anti-beta2-glycoprotein I autoantibodies. Thrombosis and Haemostasis, 1999, 81, 256-8.	1.8	8
279	The optimal therapeutic range for oral anticoagulant treatment as suggested by fibrinopeptide A (FpA) levels in patients with heart valve prostheses. European Journal of Clinical Investigation, 1989, 19, 181-184.	1.7	7
280	Anti Î²2-glycoprotein I antibodies in a patient with catastrophic antiphospholipid syndrome. Clinical Rheumatology, 1995, 14, 646-649.	1.0	7
281	Management of patients on long-term oral anticoagulant therapy undergoing elective surgery: survey of the clinical practice in the Italian anticoagulation clinics. Internal and Emergency Medicine, 2007, 2, 280-284.	1.0	7
282	The influence of factor V Leiden and G20210A prothrombin mutation on the presence of residual vein obstruction after idiopathic deep-vein thrombosis of the lower limbs. Thrombosis and Haemostasis, 2013, 109, 510-516.	1.8	7
283	Cancer as a risk factor for stroke in atrial fibrillation patients receiving long-term oral anticoagulant therapy. Thrombosis Research, 2015, 136, 488.	0.8	7
284	Contemporary Burden of Atrial Fibrillation and Associated Mortality in Northeastern Italy. American Journal of Cardiology, 2016, 118, 720-724.	0.7	7
285	Questions and Answers on Practical Thrombotic Issues in SARS-CoV-2 Infection: A Guidance Document from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology. American Journal of Cardiovascular Drugs, 2020, 20, 559-570.	1.0	7
286	Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs. European Journal of Internal Medicine, 2020, 80, 73-77.	1.0	7
287	Antibody profiles comprising anti phosphatidylserine/prothrombin differently affect thrombin generation and protein C resistance in antiphospholipid antibody carriers. Clinica Chimica Acta, 2020, 510, 796-801.	0.5	7
288	D-dimer testing and recurrent venous thromboembolism after unprovoked pulmonary embolism: A post-hoc analysis of the prolong extension study. Thrombosis and Haemostasis, 2008, 100, 718-721.	1.8	7

#	Article	IF	Citations
289	New trends in anticoagulant therapy. Israel Medical Association Journal, 2004, 6, 479-81.	0.1	7
290	Beta-thromboglobulin (Î²-TG) and platelet factor 4 (PF4) release by adenosine diphosphate (ADP) contact with native whole blood. Thrombosis Research, 1985, 39, 645-650.	0.8	6
291	Initiation of Warfarin Treatment in Outpatients with Nonrheumatic Atrial Fibrillation: A Scheme for Early Indication of Maintenance Dose. Clinical and Applied Thrombosis/Hemostasis, 1998, 4, 274-276.	0.7	6
292	Application of Wavelet Analysis to the Phonocardiographic Signal of Mechanical Heart Valve Closing Sounds. International Journal of Artificial Organs, 2009, 32, 166-172.	0.7	6
293	Comparative classification of thrombotic formations on bileaflet mechanical heart valves by phonographic analysis. Journal of Artificial Organs, 2011, 14, 100-111.	0.4	6
294	Risk of reoperation in bioprosthetic valve patients with indication for long-term anticoagulation. Results from the observational retrospective multicentre PLECTRUM study. Open Heart, 2018, 5, e000837.	0.9	6
295	General population screening for atrial fibrillation with an automated rhythm-detection blood pressure device. International Journal of Cardiology, 2021, 322, 265-270.	0.8	6
296	MiRNA 126 as a New Predictor Biomarker in Venous Thromboembolism of Persistent Residual Vein Obstruction: A Review of the Literature Plus a Pilot Study. Seminars in Thrombosis and Hemostasis, 2021, 47, 982-991.	1.5	6
297	A Novel ELISA Assay for the Detection of Anti-Prothrombin Antibodies in Antiphospholipid Syndrome Patients at High Risk of Thrombosis. Frontiers in Immunology, 2021, 12, 741589.	2.2	6
298	Monitoring oral anticoagulants: new strategies for an emerging problem. Internal and Emergency Medicine, 2006, 1, 3-4.	1.0	5
299	In vitro characterization of bileaflet Mechanical Heart Valves closing sound. , 2008, , .		5
300	Antiphospholipid syndrome classification criteria: comments on the letter of Swadzba and Musial. Journal of Thrombosis and Haemostasis, 2009, 7, 503-504.	1.9	5
301	Laboratory diagnosis of antiphospholipid syndrome. Reumatismo, 2011, 59, 187-91.	0.4	5
302	Current anticoagulant safety. Expert Opinion on Drug Safety, 2012, 11, 401-413.	1.0	5
303	Mortality associated to atrial fibrillation still on the rise: United States, 1999 to 2014. International Journal of Cardiology, 2016, 222, 788-789.	0.8	5
304	An inÂvitro model to mimic the thrombotic occlusion of small vessels in catastrophic antiphospholipid syndrome (CAPS). Lupus, 2019, 28, 1663-1668.	0.8	5
305	Benefit of dual antithrombotic therapy with direct oral anticoagulants in patients with atrial fibrillation undergoing percutaneous coronary intervention: a systematic review and metaanalysis of randomized clinical trials. Internal and Emergency Medicine, 2020, 15, 1093-1104.	1.0	5
306	Low Molecular Weight Heparin during Surgery in Parients on Long Term Oral Anticoagulant Treatment (OAT): A Prospective Observational Study.. Blood, 2004, 104, 4063-4063.	0.6	5

#	Article	IF	Citations
307	Do women with venous thromboembolism bleed more than men during anticoagulation? Data from the real-life, prospective START-Register. Therapeutic Advances in Drug Safety, 2021, 12, 204209862110629.	1.0	5
308	Interaction between Antiphospholipid Antibodies and Protein C Anticoagulant Pathway: A Narrative Review. Seminars in Thrombosis and Hemostasis, 2022, 48, 971-977.	1.5	5
309	Gender Related Differences in Gastrointestinal Bleeding With Oral Anticoagulation in Atrial Fibrillation. Journal of Cardiovascular Pharmacology and Therapeutics, 2022, 27, 107424842110546.	1.0	5
310	Ultrasound phonocardiography for detecting thrombotic formations on bileaflet mechanical heart valves. Journal of Heart Valve Disease, 2013, 22, 828-36.	0.5	5
311	Radioiodinated fibrinogen in the evaluation of patients with osteosarcoma. European Journal of Cancer, 1980, 16, 261-265.	1.0	4
312	Oral anticoagulant treatment in very elderly patients with atrial fibrillation. Comprehensive Therapy, 2001, 27, 7-10.	0.2	4
313	Anti-Î²2-glycoprotein I antibody testing in the laboratory diagnosis of antiphospholipid syndrome. Journal of Thrombosis and Haemostasis, 2005, 3, 1158-1159.	1.9	4
314	Is the Analysis Over the Time Domain or Over the Frequency Domain Significant for the Detection of Bileaflet Mechanical Heart Valve Dysfunction?. Annals of Thoracic Surgery, 2009, 87, 986-987.	0.7	4
315	Low molecular weight heparin (parnaparin) for cardioembolic events prevention in patients with atrial fibrillation undergoing elective electrical cardioversion: a prospective cohort study. Internal and Emergency Medicine, 2011, 6, 117-123.	1.0	4
316	Higher levels of plasma matrix metalloproteinase-2 are associated with a significantly increased risk of arterial thrombosis in patients with the antiphospholipid syndrome. International Journal of Cardiology, 2012, 160, 149-151.	0.8	4
317	Death rates and causes in anticoagulated atrial fibrillation patients. Journal of Cardiovascular Medicine, 2020, 21, 415-419.	0.6	4
318	The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood, 1986, 68, 869-874.	0.6	4
319	Adenosine diphosphate (ADP)-induced alpha-granules release from platelets of native whole blood is reduced by ticlopidine but not by aspirin or dipyridamole. Thrombosis and Haemostasis, 1986, 56, 147-50.	1.8	4
320	Utilization of dilute Russell's viper venom time to detect autoantibodies against beta 2-glycoprotein I which express anticoagulant activity in the presence but not in the absence of exogenous phospholipids. Thrombosis and Haemostasis, 1997, 77, 123-6.	1.8	4
321	Procoagulant effect of anti-beta2-glycoprotein I antibodies with lupus anticoagulant activity. Blood, 1999, 94, 3814-9.	0.6	4
322	Some patients with antiphospholipid syndrome express hitherto undescribed antibodies to cardiolipin-binding proteins. Thrombosis and Haemostasis, 2001, 85, 57-62.	1.8	4
323	Prevention of thromboembolism in patients with mitral stenosis and associated atrial fibrillation: effectiveness of low intensity (INR target 2) oral anticoagulant treatment. Thrombosis and Haemostasis, 2003, 89, 760-4.	1.8	4
324	Effect of Anti-Î²2Glycoprotein I Lupus Anticoagulants on Fibrin Polymerization and Fibrinolysis. Autoimmunity, 2000, 32, 39-44.	1.2	3

#	Article	IF	Citations
325	Mild inflammation may switch on again atrial fibrillation after successful electrical cardioversion. Internal and Emergency Medicine, 2009, 4, 277-278.	1.0	3
326	A Bridging Protocol in High-Thrombotic Risk Mechanical Valve Bearers Undergoing Surgery or Invasive Procedures. Journal of the American College of Cardiology, 2016, 68, 2714-2715.	1.2	3
327	Pharmacokinetic and pharmacodynamic re-evaluation of a genetic-guided warfarin trial. European Journal of Clinical Pharmacology, 2018, 74, 571-582.	0.8	3
328	Optimal Medical Therapy on Top of Dual-Antiplatelet Therapy: 1-Year Clinical Outcome in Patients With Acute Coronary Syndrome: The START Antiplatelet Registry. Angiology, 2020, 71, 235-241.	0.8	3
329	Design and rationale of a randomized, placebo-controlled trial on the efficacy and safety of sulodexide for extended treatment in elderly patients after a first venous thromboembolism. Internal and Emergency Medicine, 2021, 16, 359-368.	1.0	3
330	Enhanced â€œIn Vitroâ€œ Release of Platelet Î±-Granules After Acute Myocardial Infarction (AMI). Thrombosis and Haemostasis, 1985, 54, 544-546.	1.8	3
331	Monitoring liver regeneration after right hepatectomy. The Italian Journal of Surgical Sciences, 1985, 15, 75-7.	0.0	3
332	Thrombophilia in young patients with cryptogenic stroke and patent foramen ovale (PFO). Thrombosis and Haemostasis, 2007, 98, 906-7.	1.8	3
333	Anti-beta(2)-glycoprotein I ELISA assay: the influence of different antigen preparations. Thrombosis and Haemostasis, 2009, 101, 789-91.	1.8	3
334	Antiphospholipid Syndrome in Patients with Venous Thromboembolism. Seminars in Thrombosis and Hemostasis, 2023, 49, 833-839.	1.5	3
335	ABNORMAL MIGRATION OF SERUM ANTITHROMBIN III IN PATIENTS ON COUMARIN THERAPY BY CROSS-IMMUNOELECTROPHORESIS. British Journal of Haematology, 1981, 49, 490-492.	1.2	2
336	Mechanical Prosthetic Heart Valve Thrombosis Despite Optimal Anticoagulation in a Patient with Congenital Thrombophilia (Factor V Leiden). Clinical and Applied Thrombosis/Hemostasis, 2003, 9, 89-90.	0.7	2
337	Chronic Thromboembolic Pulmonary Hypertension. New England Journal of Medicine, 2004, 351, 1693-1693.	13.9	2
338	Long-term warfarin use to prevent both stroke and dementia in subjects with atrial fibrillation?. Journal of Thrombosis and Haemostasis, 2004, 2, 1871-1872.	1.9	2
339	New trends in anticoagulant treatments. Lupus, 2005, 14, 789-793.	0.8	2
340	Right ventricular dysfunction in patients diagnosed with pulmonary embolism. Internal and Emergency Medicine, 2010, 5, 451-452.	1.0	2
341	Dosing of Clopidogrel and Aspirin in Acute Coronary Syndromes. New England Journal of Medicine, 2010, 363, 2465-2468.	13.9	2
342	Warfarin prescription in patients with nonvalvular atrial fibrillation and one nonâ€“genderâ€related risk factor (<scp>CHA</scp>₂<scp>DS</scp>₂<scp>VAS</scp>c 1 or 2): A treatment dilemma. Cardiovascular Therapeutics, 2018, 36, e12310.	1.1	2

#	Article	IF	Citations
343	Immunological specificity and mechanism of action of IgG lupus anticoagulants. Blood, 1987, 70, 69-76.	0.6	2
344	From acute pulmonary embolism to chronic thromboembolic pulmonary hypertension. Italian Heart Journal: Official Journal of the Italian Federation of Cardiology, 2005, 6, 830-3.	0.1	2
345	D-dimer testing and recurrent venous thromboembolism after unprovoked pulmonary embolism: A post-hoc analysis of the prolong extension study. Thrombosis and Haemostasis, 2008, 100, 718-21.	1.8	2
346	An oral vitamin K protocol to reverse over-anticoagulation in patients presenting with an International Normalised Ratio above 10.0. Thrombosis and Haemostasis, 2009, 101, 410-1.	1.8	2
347	Behavior of Antithrombin III, Determined as Protein Concentration and Biologic Activity, in Subjects with Neoplastic Disease. Tumori, 1982, 68, 205-209.	0.6	1
348	Oral Anticoagulant Therapy in Patients with Atrial Fibrillation. Seminars in Vascular Medicine, 2003, 03, 333-338.	2.1	1
349	Antithrombotic strategies for atrial fibrillation: on the threshold of changes? No. Journal of Thrombosis and Haemostasis, 2005, 3, 433-435.	1.9	1
350	Positive stress test in a patient with patent coronary artery grafts. Internal and Emergency Medicine, 2006, 1, 296-299.	1.0	1
351	Prasugrel for the treatment of patients with acute coronary syndrome. Vascular Health and Risk Management, 2009, 5, 321.	1.0	1
352	Prescription of vitamin K inhibitors in low-risk patients with atrial fibrillation. Journal of Thrombosis and Thrombolysis, 2011, 31, 501-502.	1.0	1
353	Standardization of lupus anticoagulant. The Lupus Anticoagulant Sensitivity Index (LASI). Lupus, 2012, 21, 715-717.	0.8	1
354	Management of special conditions in patients on vitamin K antagonists. Internal and Emergency Medicine, 2012, 7, 407-413.	1.0	1
355	Development of Artificial Neural Networkâ€“Based Algorithms for the Classification of Bileaflet Mechanical Heart Valve Sounds. International Journal of Artificial Organs, 2012, 35, 279-287.	0.7	1
356	Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results: a reply to a rebuttal. Journal of Thrombosis and Haemostasis, 2013, 11, 1205-1206.	1.9	1
357	Pathogenesis of the antiphospholipid syndrome revisited: time to challenge the dogma: comment. Journal of Thrombosis and Haemostasis, 2016, 14, 2561-2562.	1.9	1
358	Data from a multidisciplinary poll of 178 expert physicians on the usage of non-vitamin K Oral Anticoagulants in patients with atrial fibrillation and venous thromboembolism. Data in Brief, 2017, 15, 532-539.	0.5	1
359	Risk factors for intracranial hemorrhage during vitamin K antagonist therapy in patients with nonvalvular atrial fibrillation: A caseâ€€control study. Cardiovascular Therapeutics, 2018, 36, e12458.	1.1	1
360	Oral anticoagulants in thrombotic antiphospholipid syndrome: Leave the old road for a new trail?. European Journal of Internal Medicine, 2020, 79, 29-30.	1.0	1

#	Article	IF	Citations
361	Sexâ€based difference in anticoagulated patients with mechanical prosthetic heart valves and longâ€term mortality risk. International Journal of Clinical Practice, 2021, 75, e14064.	0.8	1
362	Classification of patients with antiphospholipid syndrome into risk categories: An evolving process. Thrombosis and Haemostasis, 2006, 96, 855-856.	1.8	1
363	Task Force Report on the Management of Thrombosis in Antiphospholipid Syndrome. , 2012, , 167-179.		1
364	Variability in Exposure of Epitope G40-R43 of Domain I in Commercial Anti-Î²2-Glycoprotein I IgG Elisas Influences the Diagnosis of the Antiphospholipid Syndrome. Blood, 2012, 120, 632-632.	0.6	1
365	A brief contact of native whole blood with adenosine diphosphate (ADP) promotes the release of the contents of platelet alpha granules but not dense bodies and increases platelet retention to glass bead columns. Folia Haematologica: Internationales Magazin FÃ¼r Klinische Und Morphologische Blutforschung, 1990, 117, 359-64.	0.0	1
366	Enhanced "in vitro" release of platelet alpha-granules after acute myocardial infarction (AMI). Thrombosis and Haemostasis, 1985, 54, 544-6.	1.8	1
367	Serum of normal subjects contains IgG with antibody-like specificity for phospholipids. Folia Haematologica: Internationales Magazin FÃ¼r Klinische Und Morphologische Blutforschung, 1984, 111, 681-5.	0.0	1
368	Low intensity warfarin therapy. Haematologica, 1997, 82, 710-2.	1.7	1
369	The risk of overdiagnosis of antiphospholipid antibody syndrome. Thrombosis and Haemostasis, 2001, 86, 933.	1.8	1
370	The Evaluation of Fibrinogen Behavior in Hodgkin's Disease: Correlation with Clinical Stage. Tumori, 1983, 69, 123-127.	0.6	0
371	Do Malfunctioning Bioprosthetic Heart Valves Represent a Potential Thrombogenic Focus?. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1985, 15, 337-344.	0.5	0
372	Should patients with mitral stenosis and atrial fibrillation receive combined antithrombotic therapy?. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 412-413.	3.3	0
373	LUPUS ANTICOAGULANT TESTING. , 2007, , 733-739.		0
374	Overview of the 8th meeting of the European Forum on antiphospholipid antibodies. Lupus, 2012, 21, 693-694.	0.8	0
375	An unusual acute coronary syndrome: undisclosed disease hidden under a confounding clinical presentation. Internal and Emergency Medicine, 2012, 7, 29-31.	1.0	0
376	Lupus Anticoagulant Testing. , 2014, , 731-734.		0
377	Dyspnoea in a young woman: the opposite of every truth is just as true. Internal and Emergency Medicine, 2016, 11, 95-99.	1.0	0
378	Correlations between the enantio- and regio-selective metabolisms of warfarin. Pharmacogenomics, 2017, 18, 133-142.	0.6	0

#	Article	IF	Citations
379	Commentary. Clinical Chemistry, 2018, 64, 781-781.	1.5	0
380	The benefit of betrixaban for the extended thromboprophylaxis in acutely ill medical patients. Expert Opinion on Pharmacotherapy, 2019, 20, 261-268.	0.9	0
381	Bidimensional Immunoelectrophoresis Abnormal Migration of Serum Antithrombin III in Coumarin-Treated Patients. Thrombosis and Haemostasis, 1981, 46, 669-669.	1.8	0
382	Procoagulant Effect of Antiâ€“Î²2-Glycoprotein I Antibodies With Lupus Anticoagulant Activity. Blood, 1999, 94, 3814-3819.	0.6	0
383	A pharmacokinetic-pharmacodynamic model for individualisation of an oral anticoagulation therapy. Computer Aided Chemical Engineering, 2016, , 2313-2318.	0.3	0
384	X-Ray Crystallographic and Single-Molecule Fluorescence Studies of Beta-2 Glycoprotein I Reveal an Alternative Mechanism of Autoantibody Recognition. Blood, 2019, 134, 91-91.	0.6	0
385	Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repository. Advances in Rheumatology, 2021, 61, 64.	0.8	0
386	Bidimensional immunoelectrophoresis abnormal migration of serum antithrombin III in coumarin-treated patients. Thrombosis and Haemostasis, 1981, 46, 669.	1.8	0
387	Classification of patients with antiphospholipid syndrome into risk categories: an evolving process. Thrombosis and Haemostasis, 2006, 96, 855-6.	1.8	0
388	The Three Players of Mechanical Valve Thrombosis: Cancer, Anticancer Therapy, and Thromboprophylaxis. Journal of Heart Valve Disease, 2016, 25, 522-524.	0.5	0
389	A Prospective Study to Evaluate the Effectiveness of Edoxaban for the Resolution of Left Atrial Thrombosis in Patients with Atrial Fibrillation. Journal of Clinical Medicine, 2022, 11, 1945.	1.0	0
390	Rationale and design of a study on D-dimer use to stratify patients after a first unprovoked venous thromboembolism for their risk of recurrence: extended low-dose Apixaban given only to patients with positive D-dimer results. , 2022, 1, 38-44.		0